Table 3.
Univariate analysis for response assessment at day +30 and day +90 after azathioprine
| Hazard ratio | P | 30 days expected events (SE) | 90 days expected events (SE) | |
|---|---|---|---|---|
| Age (per decade) | 1.05 | 0.767 | ||
| 23 year | 0.048 (0.006) | 0.455 (0.061) | ||
| 38 year | 0.052 (0.005) | 0.486 (0.046) | ||
| Sex | 0.75 | 0.44 | ||
| Male | 0.043 (0.007) | 0.414 (0.069) | ||
| Female | 0.058 (0.012) | 0.552 (0.112) | ||
| Duration of ITP (years) | 0.898 (per 1 log year) | 0.569 | ||
| 1 year | 0.052 (0.004) | 0.495 (0.039) | ||
| 3 year | 0.046 (0.008) | 0.439 (0.073) | ||
| Prior therapy | 0.929 | 0.84 | ||
| ≤3 prior lines of therapy | 0.051 (0.008) | 0.488 (0.072) | ||
| >3 prior lines of therapy | 0.048 (0.011) | 0.454 (0.108) | ||
| Hemoglobin (g/dL) | 1.102 | 0.301 | ||
| 11 | 0.044 (0.009) | 0.44 (0.096) | ||
| 14 | 0.059 (0.008) | 0.6 (0.056) | ||
| WBC (/microL) | 0.944 (per 1000 WBC/microL) | 0.347 | ||
| 7900 | 0.04 (0.003) | 0.533 (0.042) | ||
| 10400 | 0.035 (0.002) | 0.463 (0.023) | ||
| Paltelets | 0.965 (per 1000 platelets/microL) | 0.326 | ||
| 8000 | 0.056 (0.006) | 0.557 (0.059) | ||
| 15000 | 0.044 (0.003) | 0.436 (0.044) |